Literature DB >> 24353357

The de ritis ratio: the test of time.

Mona Botros1, Kenneth A Sikaris1.   

Abstract

De Ritis described the ratio between the serum levels of aspartate transaminase (AST) and alanine transaminase (ALT) almost 50 years ago. While initially described as a characteristic of acute viral hepatitis where ALT was usually higher than AST, other authors have subsequently found it useful in alcoholic hepatitis, where AST is usually higher than ALT. These interpretations are far too simplistic however as acute viral hepatitis can have AST greater than ALT, and this can be a sign of fulminant disease, while alcoholic hepatitis can have ALT greater than AST when several days have elapsed since alcohol exposure. The ratio therefore represents the time course and aggressiveness of disease that would be predicted from the relatively short half-life of AST (18 h) compared to ALT (36 h). In chronic viral illnesses such as chronic viral hepatitis and chronic alcoholism as well as non-alcoholic fatty liver disease, an elevated AST/ALT ratio is predictive of long terms complications including fibrosis and cirrhosis. There are methodological issues, particularly whether or not pyridoxal phosphate is used in the transaminase assays, and although this can have specific effects when patient samples are deficient in this vitamin, these method differences generally have mild effects on the usefulness of the assays or the ratio. Ideally laboratories should be using pyridoxal phosphate supplemented assays in alcoholic, elderly and cancer patients who may be pyridoxine deplete. Ideally all laboratories reporting abnormal ALT should also report AST and calculate the De Ritis ratio because it provides useful diagnostic and prognostic information.

Entities:  

Year:  2013        PMID: 24353357      PMCID: PMC3866949     

Source DB:  PubMed          Journal:  Clin Biochem Rev        ISSN: 0159-8090


  147 in total

1.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis?

Authors:  R Pertusi; R D Dickerman; W J McConathy
Journal:  J Am Osteopath Assoc       Date:  2001-07

3.  Serum activity of mitochondrial aspartate aminotransferase: a sensitive marker of alcoholism with or without alcoholic hepatitis.

Authors:  B Nalpas; A Vassault; A Le Guillou; B Lesgourgues; N Ferry; B Lacour; P Berthelot
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

4.  The SGOT/SGPT ratio in alcoholic liver disease.

Authors:  P S Alves; E A Camilo; J P Correia
Journal:  Acta Med Port       Date:  1981 Jul-Aug

Review 5.  The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.

Authors:  Kyoko Nomura; Toshikazu Yamanouchi
Journal:  J Nutr Biochem       Date:  2011-11-29       Impact factor: 6.048

6.  Body weight, alcohol consumption and liver enzyme activity--a 4-year follow-up study.

Authors:  D H Lee; M H Ha; D C Christiani
Journal:  Int J Epidemiol       Date:  2001-08       Impact factor: 7.196

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Clinical implications of differences between two recommended procedures for determination of aspartate aminotransferase.

Authors:  J L Dols; A P van Zanten
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

9.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

Review 10.  Does fructose consumption contribute to non-alcoholic fatty liver disease?

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-07-12       Impact factor: 2.947

View more
  104 in total

1.  Genetic variants in COL13A1, ADIPOQ and SAMM50, in addition to the PNPLA3 gene, confer susceptibility to elevated transaminase levels in an admixed Mexican population.

Authors:  Elena Larrieta-Carrasco; Yvonne N Flores; Luis R Macías-Kauffer; Paula Ramírez-Palacios; Manuel Quiterio; Eric G Ramírez-Salazar; Paola León-Mimila; Berenice Rivera-Paredez; Guillermo Cabrera-Álvarez; Samuel Canizales-Quinteros; Zuo-Feng Zhang; Tania V López-Pérez; Jorge Salmerón; Rafael Velázquez-Cruz
Journal:  Exp Mol Pathol       Date:  2018-01-04       Impact factor: 3.362

2.  The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.

Authors:  Huitao Wang; Kewei Fang; Jinsong Zhang; Yongming Jiang; Guang Wang; Haiyan Zhang; Tao Chen; Xin Shi; Yuhang Li; Fei Duan; Jianhe Liu
Journal:  Int Urol Nephrol       Date:  2017-05-26       Impact factor: 2.370

3.  The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.

Authors:  Sacit Nuri Gorgel; Osman Kose; Esra Meltem Koc; Erhan Ates; Yigit Akin; Yuksel Yilmaz
Journal:  Int Urol Nephrol       Date:  2017-07-01       Impact factor: 2.370

4.  Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.

Authors:  Phimpha Paboriboune; Thomas Vial; Philavanh Sitbounlang; Stéphane Bertani; Christian Trépo; Paul Dény; Francois-Xavier Babin; Nicolas Steenkeste; Pascal Pineau; Eric Deharo
Journal:  Virol Sin       Date:  2018-06-13       Impact factor: 4.327

5.  Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Authors:  Elena L Aronovich; Kendra A Hyland; Bryan C Hall; Jason B Bell; Erik R Olson; Myra Urness Rusten; David W Hunter; N Matthew Ellinwood; R Scott McIvor; Perry B Hackett
Journal:  Hum Gene Ther       Date:  2017-05-19       Impact factor: 5.695

6.  Limited Excessive Voluntary Alcohol Drinking Leads to Liver Dysfunction in Mice.

Authors:  Scott A Wegner; Katherine A Pollard; Viktor Kharazia; David Darevsky; Luz Perez; Sanjoy Roychowdhury; Allison Xu; Dorit Ron; Laura E Nagy; Frederic Woodward Hopf
Journal:  Alcohol Clin Exp Res       Date:  2017-01-19       Impact factor: 3.455

7.  Increased liver markers are associated with higher risk of type 2 diabetes.

Authors:  Sun-Hye Ko; Myong Ki Baeg; Kyung-Do Han; Seung-Hyun Ko; Yu-Bae Ahn
Journal:  World J Gastroenterol       Date:  2015-06-28       Impact factor: 5.742

8.  Evaluation of ABO blood groups and blood-based biomarkers as a predictor of growth kinetics of renal angiomyolipoma.

Authors:  Burak Arslan; Okan Gürkan; Bugra Çetin; Öykü Aksoy Arslan; Taha Göv; Gökhan Yazıcı; Tolga Eroglu; Mustafa Asım Avcı; Enver Ozdemir
Journal:  Int Urol Nephrol       Date:  2018-10-15       Impact factor: 2.370

9.  Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Study with 1-Year Follow-up : BariScan Study.

Authors:  Felix Nickel; Christian Tapking; Laura Benner; Janina Sollors; Adrian T Billeter; Hannes G Kenngott; Loay Bokhary; Mathias Schmid; Moritz von Frankenberg; Lars Fischer; Sebastian Mueller; Beat P Müller-Stich
Journal:  Obes Surg       Date:  2018-05       Impact factor: 4.129

10.  Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease.

Authors:  Mónica Cristina García; Nicolás Eric Ponce; Liliana Maria Sanmarco; Rubén Hilario Manzo; Alvaro Federico Jimenez-Kairuz; Maria Pilar Aoki
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.